By Sabela Ojea
Tevogen Bio said it is delaying the publication of its filing third-quarter filing with the Securities and Exchange Commission, citing material weaknesses in its internal controls over financial reporting.
The biotechnology company on Friday said the delay follows a recent change in the third party firm in charge of a portion of its internal accounting and financing reporting.
Overall for the third quarter, the company expects to post a loss of about $4.3 million for the first nine months of 2024, down from a loss of $56.8 million for the same period a year earlier.
The news come a day after founder and Chief Executive Ryan Saadi suggested the company needed to raise capital.
"Founders must navigate the need for capital to fuel growth with a vigilant eye on avoiding equity dilution," Saadi said. "Our financing options must consider preserving shareholder value and the potential equity dilution of warrant conversion at a strike price of $11.50 per share."
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
November 15, 2024 17:26 ET (22:26 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。